China’s oncology drugs market is poised for significant growth, projected to reach USD 42.19 billion by 2028. As the second-largest pharmaceutical market globally, China Oncology Drugs Market China’s biopharmaceutical sector is undergoing rapid transformation. The government is prioritizing healthcare and innovation to tackle the rising cancer burden and promote a healthier population. However, challenges like high treatment costs, limited insurance coverage, and awareness gaps pose barriers to accessible cancer care.
Key Market Drivers
- Growing Cancer Incidence
With an aging population and rising risk factors—such as smoking, obesity, and environmental pollutants—China faces an increasing cancer burden. Lung cancer, largely due to smoking, remains the leading cause of cancer-related deaths, while rates of colorectal, prostate, and breast cancers are also rising. In 2022, China recorded approximately 4.82 million new cancer cases and 3.21 million cancer-related deaths. The “Health